STM Journals Peer-reviewed research from Consortium e-Learning Network

Trends in Drug Delivery Original Research

Overview of Recent Advancement of Nano Stent in Pharmaceutical Application

  1. A. Mohamed Sikkander Velammal Engineering College

Abstract

Interventional cardiology has witnessed remarkable progress with the evolution of nanotechnology, leading to the development of nanostents. Nanostents, characterized by their nanoscale features and innovative materials, have emerged as a cutting-edge solution for addressing the limitations associated with traditional stent technologies. This thorough analysis examines the most recent developments in the design, manufacture, and use of nanostents, emphasizing how they may completely transform vascular interventions. The first section of the review provides an overview of the nonmaterial’s employed in nanostent construction, including biocompatible polymers, advanced alloys, and bioresorbable elements. These materials contribute to enhanced biocompatibility, reduced inflammation, and improved long-term outcomes. The incorporation of nanoscale surface modifications further optimizes the interaction between the nanostent and the vascular environment, promoting quicker endothelialization and minimizing the risk of restenosis. The second part of the review delves into the engineering innovations that have enabled the development of smart nanostents. These devices are equipped with sensors and actuators, allowing for real-time monitoring of vascular conditions and responsive adjustments to optimize therapeutic outcomes. Additionally, the integration of nanotechnology enables precise drug delivery strategies, ensuring targeted and controlled release of pharmaceutical agents to the site of intervention. Clinical studies and preclinical experiments supporting the efficacy and safety of nanostents are systematically reviewed in the third section. Comparative analyses with conventional stents reveal promising results, showcasing the potential of nano stents in reducing complications, such as thrombosis and restenosis, while improving patient outcomes.

Keywords

References (158)

  1. Jeewandara T, Wise S, Ng M. Biocompatibility of Coronary Stents. Materials. 2014;7(2):769-786. doi:10.3390/ma7020769
  2. Karimi M, Zare H, Bakhshian Nik A, Yazdani N, Hamrang M, Mohamed E, et al. Nanotechnology in Diagnosis and Treatment of Coronary Artery Disease. Nanomedicine. 2016;11(5):513-530. doi:10.2217/nnm.16.3
  3. Yin RX, Yang DZ, Wu JZ. Nanoparticle Drug- and Gene-eluting Stents for the Prevention and Treatment of Coronary Restenosis. Theranostics. 2014;4(2):175-200. doi:10.7150/thno.7210
  4. Malik, T.F.; Tivakaran, V.S. Percutaneous Transluminal Coronary Angioplasty [PTCA]; StatPearls: Treasure Island, FL, USA, 2019.
  5. Claessen BE, Henriques JPS, Jaffer FA, Mehran R, Piek JJ, Dangas GD. Stent Thrombosis. JACC: Cardiovascular Interventions. 2014;7(10):1081-1092. doi:10.1016/j.jcin.2014.05.016
  6. Alfonso F, Byrne RA, Rivero F, Kastrati A. Current Treatment of In-Stent Restenosis. Journal of the American College of Cardiology. 2014;63(24):2659-2673. doi:10.1016/j.jacc.2014.02.545
  7. Wessely R, Schömig A, Kastrati A. Sirolimus and Paclitaxel on Polymer-Based Drug-Eluting Stents. Journal of the American College of Cardiology. 2006;47(4):708-714. doi:10.1016/j.jacc.2005.09.047
  8. Boon GD. An Overview of Hemostasis. Toxicologic Pathology. 1993;21(2):170-179. doi:10.1177/019262339302100209
  9. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proceedings of the National Academy of Sciences. 1999;96(20):11189-11193. doi:10.1073/pnas.96.20.11189
  10. Mohammad SF, Anderson WH, Smith JB, Chuang HY, Mason RG. Effects of heparin on platelet aggregation and release and thromboxane A2 production. Am J Pathol. 1981 Aug;104[2]:132-41.
  11. Karimzadeh Jouzdani, M., Karimzadeh Jouzdani, M., & Mohebbi, B. [2021]. The Role of Inflammatory Biomarkers in Predicting in-Stent Restenosis. Journal of Medicinal and Chemical Sciences, 4[6], 635-645. doi:10.26655/JMCHEMSCI.2021.6.12
  12. Milani Fard, A. M., & Milani Fard, M. [2022]. Evaluation of Office Stones in Kidney Patients and How to form and Treat Them. Eurasian Journal of Science and Technology, 2[2], 111-125. doi:10.22034/EJST.2022.2.1
  13. Ahmadi, A., Ghanbari, H., Salem, M. M., Milani Fard, A. M., & Barkhordari, K. [2022]. The Outcome of the Correction of Anterior Vocal Cord Web by Flap Technique using Real Anterior Vocal Cord Base in Frontolateral Laryngectomy in Patients with Glottis Cancer. Eurasian Journal of Science and Technology, 2[4], 262-267. doi:10.22034/EJST.2022.4.4
  14. Dousti, M., Alizadeh Otaghvar, H., Jafarian, A., Rokhzadi, I., Mazhari, N., & Moghaddam, S. [2021]. Evaluation of the Effect of Gummy Candy on Postoperative Ileus and Its Complications. Journal of Medicinal and Chemical Sciences, 4[6], 579-585. doi:10.26655/JMCHEMSCI.2021.6.6
  15. Najdsepas, H., Rahimzadeh, N., haghighikian, M., Maddahali, M., & Milani Fard, M. [2022]. Comparison of Catheter Functionality and Post-Procedural Consequences in Vascular Access Through Saphenofemoral Cutdown and Percutaneus Jugu-lar Vein Catheterization among Children and Neonates. Eurasian Journal of Science and Technology, 2[3], 176-184. doi:10.22034/EJST.2022.2.6
  16. Dahlbäck B. Progress in the Understanding of the Protein C Anticoagulant Pathway. International Journal of Hematology. 2004;79(2):109-116. doi:10.1532/ijh97.03149
  17. WRIGHT IS. The nomenclature of blood clotting factors. Can Med Assoc J. 1962 Feb 24;86[8]:373-4.
  18. Eilertsen KE, Østerud B. Tissue factor. Blood Coagulation & Fibrinolysis. 2004;15(7):521-538. doi:10.1097/00001721-200410000-00001
  19. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, et al. Drug-Eluting Stent and Coronary Thrombosis. Circulation. 2007;115(8):1051-1058. doi:10.1161/circulationaha.106.675934
  20. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451(7181):914-918. doi:10.1038/nature06797
  21. Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI. Vascular Inflammation and Repair. JACC: Cardiovascular Interventions. 2011;4(10):1057-1066. doi:10.1016/j.jcin.2011.05.025
  22. Gori T, Polimeni A, Indolfi C, Räber L, Adriaenssens T, Münzel T. Predictors of stent thrombosis and their implications for clinical practice. Nature Reviews Cardiology. 2018;16(4):243-256. doi:10.1038/s41569-018-0118-5
  23. Padmanabhan J, Kyriakides TR. Nanomaterials, Inflammation, and Tissue Engineering. WIREs Nanomedicine and Nanobiotechnology. 2014;7(3):355-370. doi:10.1002/wnan.1320
  24. Chopra H, Bibi S, Mishra AK, Tirth V, Yerramsetty SV, Murali SV, et al. Nanomaterials: A Promising Therapeutic Approach for Cardiovascular Diseases. Journal of Nanomaterials. 2022;2022(1). doi:10.1155/2022/4155729
  25. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017;9(6):7204-7218. doi:10.18632/oncotarget.23208
  26. Ansar W, Ghosh S. C-reactive protein and the biology of disease. Immunologic Research. 2013;56(1):131-142. doi:10.1007/s12026-013-8384-0
  27. Medzhitov R. Inflammation 2010: New Adventures of an Old Flame. Cell. 2010;140(6):771-776. doi:10.1016/j.cell.2010.03.006
  28. Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the etiology of disease across the life span. Nature Medicine. 2019;25(12):1822-1832. doi:10.1038/s41591-019-0675-0
  29. Renz H, Holt PG, Inouye M, Logan AC, Prescott SL, Sly PD. An exposome perspective: Early-life events and immune development in a changing world. Journal of Allergy and Clinical Immunology. 2017;140(1):24-40. doi:10.1016/j.jaci.2017.05.015
  30. Fleming TP, Watkins AJ, Velazquez MA, Mathers JC, Prentice AM, Stephenson J, Barker M, Saffery R, Yajnik CS, Eckert JJ, Hanson MA, Forrester T, Gluckman PD, Godfrey KM. Origins of lifetime health around the time of conception: causes and consequences. Lancet. 2018 May 5;391[10132]:1842-1852. doi:10.1016/S0140-6736[18]30312-X.
  31. Miller GE, Chen E, Parker KJ. Psychological stress in childhood and susceptibility to the chronic diseases of aging: Moving toward a model of behavioral and biological mechanisms. Psychological Bulletin. 2011;137(6):959-997. doi:10.1037/a0024768
  32. Nathan C, Ding A. Nonresolving Inflammation. Cell. 2010;140(6):871-882. doi:10.1016/j.cell.2010.02.029
  33. Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. Breast Cancer: Basic and Clinical Research. 2015;9s2:BCBCR.S29420. doi:10.4137/bcbcr.s29420
  34. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine: Nanotechnology, Biology and Medicine. 2007;3(1):20-31. doi:10.1016/j.nano.2006.11.008
  35. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Nanomedicine: Current status and future prospects. FASEB J. 2005, 19, 311–330.
  36. Malik S, Muhammad K, Waheed Y. Nanotechnology: A Revolution in Modern Industry. Molecules. 2023;28(2):661. doi:10.3390/molecules28020661
  37. Patel SK, Janjic JM. Macrophage Targeted Theranostics as Personalized Nanomedicine Strategies for Inflammatory Diseases. Theranostics. 2015;5(2):150-172. doi:10.7150/thno.9476
  38. Yin RX, Yang DZ, Wu JZ. Nanoparticle Drug- and Gene-eluting Stents for the Prevention and Treatment of Coronary Restenosis. Theranostics. 2014;4(2):175-200. doi:10.7150/thno.7210
  39. Borhani S, Hassanajili S, Ahmadi Tafti SH, Rabbani S. Cardiovascular stents: overview, evolution, and next generation. Progress in Biomaterials. 2018;7(3):175-205. doi:10.1007/s40204-018-0097-y
  40. Borhani S, Hassanajili S, Ahmadi Tafti SH, Rabbani S. Cardiovascular stents: overview, evolution, and next generation. Progress in Biomaterials. 2018;7(3):175-205. doi:10.1007/s40204-018-0097-y
  41. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. 1978 Feb 4;1[8058]:263. doi:10.1016/s0140-6736[78]90500-7.
  42. Sigwart U, Urban P, Golf S, Kaufmann U, Imbert C, Fischer A, et al. Emergency stenting for acute occlusion after coronary balloon angioplasty. Circulation. 1988;78(5):1121-1127. doi:10.1161/01.cir.78.5.1121
  43. Palmaz JC, Kopp DT, Hayashi H, Schatz RA, Hunter G, Tio FO, et al. Normal and stenotic renal arteries: experimental balloon-expandable intraluminal stenting. Radiology. 1987;164(3):705-708. doi:10.1148/radiology.164.3.2956628
  44. Puranik AS, Dawson ER, Peppas NA. Recent advances in drug eluting stents. International Journal of Pharmaceutics. 2013;441(1-2):665-679. doi:10.1016/j.ijpharm.2012.10.029
  45. Buccheri D, Piraino D, Andolina G, Cortese B. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. Journal of Thoracic Disease. 2016;8(10):E1150-E1162. doi:10.21037/jtd.2016.10.93
  46. Hu T, Yang J, Cui K, Rao Q, Yin T, Tan L, et al. Controlled Slow-Release Drug-Eluting Stents for the Prevention of Coronary Restenosis: Recent Progress and Future Prospects. ACS Applied Materials & Interfaces. 2015;7(22):11695-11712. doi:10.1021/acsami.5b01993
  47. Ferns GAA, Avades TY. The mechanisms of coronary restenosis: insights from experimental models. International Journal of Experimental Pathology. 2000;81(2):63-88. doi:10.1046/j.1365-2613.2000.00143.x
  48. Borhani S, Hassanajili S, Ahmadi Tafti SH, Rabbani S. Cardiovascular stents: overview, evolution, and next generation. Progress in Biomaterials. 2018;7(3):175-205. doi:10.1007/s40204-018-0097-y
  49. Rykowska I, Nowak I, Nowak R. Drug-Eluting Stents and Balloons—Materials, Structure Designs, and Coating Techniques: A Review. Molecules. 2020;25(20):4624. doi:10.3390/molecules25204624
  50. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. 1978 Feb 4;1[8058]:263. doi:10.1016/s0140-6736[78]90500-7. PMID: 74678.
  51. Palmaz JC, Kopp DT, Hayashi H, Schatz RA, Hunter G, Tio FO, et al. Normal and stenotic renal arteries: experimental balloon-expandable intraluminal stenting. Radiology. 1987;164(3):705-708. doi:10.1148/radiology.164.3.2956628
  52. Betancourt T, Brannon-Peppas L. Micro- and nanofabrication methods in nanotechnological medical and pharmaceutical devices. International Journal of Nanomedicine. 2006;1(4):483-495. doi:10.2147/nano.2006.1.4.483
  53. Fox KAA, Metra M, Morais J, Atar D. The myth of ‘stable’ coronary artery disease. Nature Reviews Cardiology. 2019;17(1):9-21. doi:10.1038/s41569-019-0233-y
  54. Mikulewicz M, Chojnacka K. Cytocompatibility of Medical Biomaterials Containing Nickel by Osteoblasts: a Systematic Literature Review. Biological Trace Element Research. 2010;142(3):865-889. doi:10.1007/s12011-010-8798-7
  55. Savage DT, Hilt JZ, Dziubla TD. In Vitro Methods for Assessing Nanoparticle Toxicity. Methods in Molecular Biology. 2018:1-29. doi:10.1007/978-1-4939-8916-4_1
  56. Goel SS, Dilip Gajulapalli R, Athappan G, Philip F, Gupta S, Murat Tuzcu E, et al. Management of drug eluting stent in‐stent restenosis: A systematic review and meta‐analysis. Catheterization and Cardiovascular Interventions. 2015;87(6):1080-1091. doi:10.1002/ccd.26151
  57. Yin RX, Yang DZ, Wu JZ. Nanoparticle Drug- and Gene-eluting Stents for the Prevention and Treatment of Coronary Restenosis. Theranostics. 2014;4(2):175-200. doi:10.7150/thno.7210
  58. Kempin W, Kaule S, Reske T, Grabow N, Petersen S, Nagel S, et al. In vitro evaluation of paclitaxel coatings for delivery via drug-coated balloons. European Journal of Pharmaceutics and Biopharmaceutics. 2015;96:322-328. doi:10.1016/j.ejpb.2015.08.010
  59. Kraitzer A, Kloog Y, Zilberman M. Approaches for prevention of restenosis. Journal of Biomedical Materials Research Part B: Applied Biomaterials. 2007;85B(2):583-603. doi:10.1002/jbm.b.30974
  60. Zheng F, Xiong W, Sun S, Zhang P, Zhu JJ. Recent advances in drug release monitoring. Nanophotonics. 2018;8(3):391-413. doi:10.1515/nanoph-2018-0219
  61. Hu T, Yang J, Cui K, Rao Q, Yin T, Tan L, et al. Controlled Slow-Release Drug-Eluting Stents for the Prevention of Coronary Restenosis: Recent Progress and Future Prospects. ACS Applied Materials & Interfaces. 2015;7(22):11695-11712. doi:10.1021/acsami.5b01993
  62. Torrado J, Buckley L, Durán A, Trujillo P, Toldo S, Valle Raleigh J, et al. Restenosis, Stent Thrombosis, and Bleeding Complications. Journal of the American College of Cardiology. 2018;71(15):1676-1695. doi:10.1016/j.jacc.2018.02.023
  63. Iqbal J, Chamberlain J, Francis SE, Gunn J. Role of Animal Models in Coronary Stenting. Annals of Biomedical Engineering. 2015;44(2):453-465. doi:10.1007/s10439-015-1414-4
  64. Abbasnezhad N, Zirak N, Champmartin S, Shirinbayan M, Bakir F. An Overview of In Vitro Drug Release Methods for Drug-Eluting Stents. Polymers. 2022;14(13):2751. doi:10.3390/polym14132751
  65. Sun D, Zheng Y, Yin T, Tang C, Yu Q, Wang G. Coronary drug‐eluting stents: From design optimization to newer strategies. Journal of Biomedical Materials Research Part A. 2013;102(5):1625-1640. doi:10.1002/jbm.a.34806
  66. Wang PJ, Ferralis N, Conway C, Grossman JC, Edelman ER. Strain-induced accelerated asymmetric spatial degradation of polymeric vascular scaffolds. Proceedings of the National Academy of Sciences. 2018;115(11):2640-2645. doi:10.1073/pnas.1716420115
  67. Bozsak F, Chomaz JM, Barakat AI. Modeling the transport of drugs eluted from stents: physical phenomena driving drug distribution in the arterial wall. Biomechanics and Modeling in Mechanobiology. 2014;13(2):327-347. doi:10.1007/s10237-013-0546-4
  68. Garg S, Serruys PW. Coronary Stents. Journal of the American College of Cardiology. 2010;56(10):S1-S42. doi:10.1016/j.jacc.2010.06.007
  69. Premer C, Kanelidis AJ, Hare JM, Schulman IH. Rethinking Endothelial Dysfunction as a Crucial Target in Fighting Heart Failure. Mayo Clinic Proceedings: Innovations, Quality & Outcomes. 2019;3(1):1-13. doi:10.1016/j.mayocpiqo.2018.12.006
  70. Kim SM, Park KS, Lih E, Hong YJ, Kang JH, Kim IH, et al. Fabrication and characteristics of dual functionalized vascular stent by spatio-temporal coating. Acta Biomaterialia. 2016;38:143-152. doi:10.1016/j.actbio.2016.04.029
  71. Smith BR, Edelman ER. Nanomedicines for cardiovascular disease. Nature Cardiovascular Research. 2023;2(4):351-367. doi:10.1038/s44161-023-00232-y
  72. Puranik AS, Dawson ER, Peppas NA. Recent advances in drug eluting stents. International Journal of Pharmaceutics. 2013;441(1-2):665-679. doi:10.1016/j.ijpharm.2012.10.029
  73. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. Journal of Nanobiotechnology. 2018;16(1). doi:10.1186/s12951-018-0392-8
  74. Saleh YE, Gepreel MA, Allam NK. Functional Nanoarchitectures For Enhanced Drug Eluting Stents. Scientific Reports. 2017;7(1). doi:10.1038/srep40291
  75. Buccheri D, Piraino D, Andolina G, Cortese B. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. Journal of Thoracic Disease. 2016;8(10):E1150-E1162. doi:10.21037/jtd.2016.10.93
  76. Wilson S, Mone P, Kansakar U, Jankauskas SS, Donkor K, Adebayo A, et al. Diabetes and restenosis. Cardiovascular Diabetology. 2022;21(1). doi:10.1186/s12933-022-01460-5
  77. Iqbal J, Gunn J, Serruys PW. Coronary stents: historical development, current status and future directions. British Medical Bulletin. 2013;106(1):193-211. doi:10.1093/bmb/ldt009
  78. Bassous N, Cooke JP, Webster TJ. Enhancing Stent Effectiveness with Nanofeatures. Methodist DeBakey Cardiovascular Journal. 2016;12(3):163. doi:10.14797/mdcj-12-3-163
  79. Zong J, He Q, Liu Y, Qiu M, Wu J, Hu B. Advances in the development of biodegradable coronary stents: A translational perspective. Materials Today Bio. 2022;16:100368. doi:10.1016/j.mtbio.2022.100368
  80. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. Circulation. 2020;141(9). doi:10.1161/cir.0000000000000757
  81. Beshchasna N, Saqib M, Kraskiewicz H, Wasyluk Ł, Kuzmin O, Duta OC, et al. Recent Advances in Manufacturing Innovative Stents. Pharmaceutics. 2020;12(4):349. doi:10.3390/pharmaceutics12040349
  82. Haben C, Park WM, Bena JF, Parodi FE, Lyden SP. Improving midterm results justify the continued use of bare-metal stents for endovascular therapy for chronic mesenteric ischemia. Journal of Vascular Surgery. 2020;71(1):111-120. doi:10.1016/j.jvs.2019.01.094
  83. Chen Y, Gao P, Huang L, Tan X, Zhou N, Yang T, et al. A tough nitric oxide-eluting hydrogel coating suppresses neointimal hyperplasia on vascular stent. Nature Communications. 2021;12(1). doi:10.1038/s41467-021-27368-4
  84. Claessen BE, Henriques JPS, Jaffer FA, Mehran R, Piek JJ, Dangas GD. Stent Thrombosis. JACC: Cardiovascular Interventions. 2014;7(10):1081-1092. doi:10.1016/j.jcin.2014.05.016
  85. Tsai ML, Hsieh MJ, Chen CC, Chang SH, Wang CY, Chen DY, Yang CH, Yeh JK, Ho MY, Hsieh IC. Comparison of 9-Month Angiographic Follow-Up and Long-Term Clinical Outcomes of Biodegradable Polymer Drug-Eluting Stents and Second-Generation Durable Polymer Drug-Eluting Stents in Patients Undergoing Single Coronary Artery Stenting. Acta Cardiol Sin. 2020 Mar;36[2]:97-104. doi:10.6515/ACS.202003_36[2].
  86. De Luca G, Smits P, Hofma SH, Di Lorenzo E, Vlachojannis GJ, van't Hof AWJ, et al. Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: A pooled patient-level meta-analysis of randomized trials. International Journal of Cardiology. 2017;244:121-127. doi:10.1016/j.ijcard.2017.06.022
  87. Torii S, Jinnouchi H, Sakamoto A, Mori H, Park J, Amoa FC, et al. Vascular responses to coronary calcification following implantation of newer-generation drug-eluting stents in humans: impact on healing. European Heart Journal. 2019;41(6):786-796. doi:10.1093/eurheartj/ehz850
  88. Yue R, Niu J, Li Y, Ke G, Huang H, Pei J, et al. In vitro cytocompatibility, hemocompatibility and antibacterial properties of biodegradable Zn-Cu-Fe alloys for cardiovascular stents applications. Materials Science and Engineering: C. 2020;113:111007. doi:10.1016/j.msec.2020.111007
  89. Beshchasna N, Saqib M, Kraskiewicz H, Wasyluk Ł, Kuzmin O, Duta OC, et al. Recent Advances in Manufacturing Innovative Stents. Pharmaceutics. 2020;12(4):349. doi:10.3390/pharmaceutics12040349
  90. Omar WA, Kumbhani DJ. The Current Literature on Bioabsorbable Stents: a Review. Current Atherosclerosis Reports. 2019;21(12). doi:10.1007/s11883-019-0816-4
  91. Sotomi Y, Onuma Y, Collet C, Tenekecioglu E, Virmani R, Kleiman NS, et al. Bioresorbable Scaffold. Circulation Research. 2017;120(8):1341-1352. doi:10.1161/circresaha.117.310275
  92. Wang Y, Zhai W, Cheng S, Li J, Zhang H. Surface-functionalized design of blood-contacting biomaterials for preventing coagulation and promoting hemostasis. Friction. 2023;11(8):1371-1394. doi:10.1007/s40544-022-0710-x
  93. Wang C, He T, Zhou H, Zhang Z, Lee C. Artificial intelligence enhanced sensors - enabling technologies to next-generation healthcare and biomedical platform. Bioelectronic Medicine. 2023;9(1). doi:10.1186/s42234-023-00118-1
  94. Lin W, Zhang H, Zhang W, Qi H, Zhang G, Qian J, et al. In vivo degradation and endothelialization of an iron bioresorbable scaffold. Bioactive Materials. 2021;6(4):1028-1039. doi:10.1016/j.bioactmat.2020.09.020
  95. L'Heureux N, Dusserre N, Konig G, Victor B, Keire P, Wight TN, et al. Human tissue-engineered blood vessels for adult arterial revascularization. Nature Medicine. 2006;12(3):361-365. doi:10.1038/nm1364
  96. Im SH, Jung Y, Kim SH. Current status and future direction of biodegradable metallic and polymeric vascular scaffolds for next-generation stents. Acta Biomaterialia. 2017;60:3-22. doi:10.1016/j.actbio.2017.07.019
  97. Hoare D, Bussooa A, Neale S, Mirzai N, Mercer J. The Future of Cardiovascular Stents: Bioresorbable and Integrated Biosensor Technology. Advanced Science. 2019;6(20). doi:10.1002/advs.201900856
  98. Li J, Long Y, Yang F, Wei H, Zhang Z, Wang Y, et al. Multifunctional Artificial Artery from Direct 3D Printing with Built‐In Ferroelectricity and Tissue‐Matching Modulus for Real‐Time Sensing and Occlusion Monitoring. Advanced Functional Materials. 2020;30(39). doi:10.1002/adfm.202002868
  99. Vahabli E, Mann J, Heidari BS, Lawrence‐Brown M, Norman P, Jansen S, et al. The Technological Advancement to Engineer Next‐Generation Stent‐Grafts: Design, Material, and Fabrication Techniques. Advanced Healthcare Materials. 2022;11(13). doi:10.1002/adhm.202200271
  100. El-Safty SA, Shenashen MA. Nanoscale dynamic chemical, biological sensor material designs for control monitoring and early detection of advanced diseases. Materials Today Bio. 2020;5:100044. doi:10.1016/j.mtbio.2020.100044
  101. Khalaj R, Tabriz AG, Okereke MI, Douroumis D. 3D printing advances in the development of stents. International Journal of Pharmaceutics. 2021;609:121153. doi:10.1016/j.ijpharm.2021.121153
  102. Yeazel TR, Becker ML. Advancing Toward 3D Printing of Bioresorbable Shape Memory Polymer Stents. Biomacromolecules. 2020;21(10):3957-3965. doi:10.1021/acs.biomac.0c01082
  103. Zhang C, Cai D, Liao P, Su JW, Deng H, Vardhanabhuti B, et al. 4D Printing of shape-memory polymeric scaffolds for adaptive biomedical implantation. Acta Biomaterialia. 2021;122:101-110. doi:10.1016/j.actbio.2020.12.042
  104. Bowen PK, Shearier ER, Zhao S, Guillory RJ, Zhao F, Goldman J, et al. Biodegradable Metals for Cardiovascular Stents: from Clinical Concerns to Recent Zn‐Alloys. Advanced Healthcare Materials. 2016;5(10):1121-1140. doi:10.1002/adhm.201501019
  105. Mostaed E, Sikora-Jasinska M, Drelich JW, Vedani M. Zinc-based alloys for degradable vascular stent applications. Acta Biomaterialia. 2018;71:1-23. doi:10.1016/j.actbio.2018.03.005
  106. Camasão DB, Mantovani D. The mechanical characterization of blood vessels and their substitutes in the continuous quest for physiological-relevant performances. A critical review. Materials Today Bio. 2021;10:100106. doi:10.1016/j.mtbio.2021.100106
  107. Sensini A, Gualandi C, Focarete ML, Belcari J, Zucchelli A, Boyle L, et al. Multiscale hierarchical bioresorbable scaffolds for the regeneration of tendons and ligaments. Biofabrication. 2019;11(3):035026. doi:10.1088/1758-5090/ab20ad
  108. Bangalore S, Bezerra HG, Rizik DG, Armstrong EJ, Samuels B, Naidu SS, et al. The State of the Absorb Bioresorbable Scaffold. JACC: Cardiovascular Interventions. 2017;10(23):2349-2359. doi:10.1016/j.jcin.2017.09.041
  109. Zong J, He Q, Liu Y, Qiu M, Wu J, Hu B. Advances in the development of biodegradable coronary stents: A translational perspective. Materials Today Bio. 2022;16:100368. doi:10.1016/j.mtbio.2022.100368
  110. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular Stents to Prevent Occlusion and Re-Stenosis after Transluminal Angioplasty. New England Journal of Medicine. 1987;316(12):701-706. doi:10.1056/nejm198703193161201
  111. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease. New England Journal of Medicine. 1994;331(8):496-501. doi:10.1056/nejm199408253310802
  112. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease. New England Journal of Medicine. 1994;331(8):489-495. doi:10.1056/nejm199408253310801
  113. Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, Yokoi H, Hamasaki N, Horiuchi H, Ohishi H. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol. 1988 Sep;12[3]:616-23. doi:10.1016/s0735-1097[88]80046-9.
  114. Serruys PW, Luijten HE, Beatt KJ, et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon: a quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation.1988; 77:361–371.
  115. Kimura T, Yokoi H, Nakagawa Y, et al. Three- year follow-up after implantation of metallic coronary-artery stents. N Engl J Med.1996; 334:561–566.
  116. Van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary artery. Circulation.1996; 94:1690–1697.
  117. Lincoff AM, Furst JG, Ellis SG, et al. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol.1997; 29:808–816.
  118. Yamawaki T, Shimokawa H, Kozai T, et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol.1998; 32:780–786.
  119. Murphy JG, Schwartz RS, Edwards WD, et al. Percutaneous polymeric stents in porcine coronary arteries: initial experience with polyethylene terephthalate stent. Circulation.1992; 86:1596–1604.
  120. Karas SP, Gravanis MB, Santonian EC, et al. Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol.1992; 20:467–474.
  121. Tamai H, Igaki K, Tsuji T, et al. A biodegradable poly-l-lactic acid coronary stent in porcine coronary artery. J Interv Cardiol.1999; 12:443–450.
  122. Currier JW, Faxon DP. Restenosis after percutaneous transluminal coronary angioplasty: have we been aiming at the wrong target? J Am Coll Cardiol.1995; 25:516–520.
  123. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Chiu Wong S, et al. Arterial Remodeling After Coronary Angioplasty. Circulation. 1996;94(1):35-43. doi:10.1161/01.cir.94.1.35
  124. Lansky AJ, Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Baim DS, Kuntz RE, Simonton C, Bersin RM, Hinohara T, Fitzgerald PJ, Leon MB. Remodeling after directional coronary atherectomy [with and without adjunct percutaneous transluminal coronary angioplasty]: a serial angiographic and intravascular ultrasound analysis from the Optimal Atherectomy Restenosis Study. J Am Coll Cardiol. 1998 Aug;32[2]:329-37. doi:10.1016/s0735-1097[98]00245-9.
  125. Schakenraad JM, Oosterbaan JA, Nieuwenhuis P, Molenaar I, Olijslager J, Potman W, Eenink MJ, Feijen J. Biodegradable hollow fibres for the controlled release of drugs. Biomaterials. 1988 Jan;9[1]:116-20. doi:10.1016/0142-9612[88]90082-8
  126. Schakenraad JM, Hardonk MJ, Feijen J, Molenaar I, Nieuwenhuis P. Enzymatic activity toward poly(L‐lactic acid) implants. Journal of Biomedical Materials Research. 1990;24(5):529-545. doi:10.1002/jbm.820240502
  127. Moravej M, Mantovani D. Biodegradable Metals for Cardiovascular Stent Application: Interests and New Opportunities. International Journal of Molecular Sciences. 2011;12(7):4250-4270. doi:10.3390/ijms12074250
  128. Rykowska I, Nowak I, Nowak R. Drug-Eluting Stents and Balloons—Materials, Structure Designs, and Coating Techniques: A Review. Molecules. 2020;25(20):4624. doi:10.3390/molecules25204624
  129. Beshchasna N, Saqib M, Kraskiewicz H, Wasyluk Ł, Kuzmin O, Duta OC, et al. Recent Advances in Manufacturing Innovative Stents. Pharmaceutics. 2020;12(4):349. doi:10.3390/pharmaceutics12040349
  130. Wang L, Jiao L, Pang S, Yan P, Wang X, Qiu T. The Development of Design and Manufacture Techniques for Bioresorbable Coronary Artery Stents. Micromachines. 2021;12(8):990. doi:10.3390/mi12080990
  131. McDowell G, Slevin M, Krupinski J. Nanotechnology for the treatment of coronary in stent restenosis: a clinical perspective. Vascular Cell. 2011;3(1):8. doi:10.1186/2045-824x-3-8
  132. Bassous N, Cooke JP, Webster TJ. Enhancing Stent Effectiveness with Nanofeatures. Methodist DeBakey Cardiovascular Journal. 2016;12(3):163. doi:10.14797/mdcj-12-3-163
  133. Yin RX, Yang DZ, Wu JZ. Nanoparticle Drug- and Gene-eluting Stents for the Prevention and Treatment of Coronary Restenosis. Theranostics. 2014;4(2):175-200. doi:10.7150/thno.7210
  134. Cherian AM, Nair SV, Maniyal V, Menon D. Surface engineering at the nanoscale: A way forward to improve coronary stent efficacy. APL Bioengineering. 2021;5(2). doi:10.1063/5.0037298
  135. Smith BR, Edelman ER. Nanomedicines for cardiovascular disease. Nature Cardiovascular Research. 2023;2(4):351-367. doi:10.1038/s44161-023-00232-y
  136. Sahoo J, Sarkhel S, Mukherjee N, Jaiswal A. Nanomaterial-Based Antimicrobial Coating for Biomedical Implants: New Age Solution for Biofilm-Associated Infections. ACS Omega. 2022;7(50):45962-45980. doi:10.1021/acsomega.2c06211
  137. Bassous N, Cooke JP, Webster TJ. Enhancing Stent Effectiveness with Nanofeatures. Methodist DeBakey Cardiovascular Journal. 2016;12(3):163. doi:10.14797/mdcj-12-3-163
  138. Raikar AS, Priya S, Bhilegaonkar SP, Somnache SN, Kalaskar DM. Surface Engineering of Bioactive Coatings for Improved Stent Hemocompatibility: A Comprehensive Review. Materials. 2023;16(21):6940. doi:10.3390/ma16216940
  139. Cherian AM, Nair SV, Maniyal V, Menon D. Surface engineering at the nanoscale: A way forward to improve coronary stent efficacy. APL Bioengineering. 2021;5(2). doi:10.1063/5.0037298
  140. Hara H, Nakamura M, Palmaz JC, Schwartz RS. Role of stent design and coatings on restenosis and thrombosis. Advanced Drug Delivery Reviews. 2006;58(3):377-386. doi:10.1016/j.addr.2006.01.022
  141. Govindarajan T, Shandas R. A Survey of Surface Modification Techniques for Next-Generation Shape Memory Polymer Stent Devices. Polymers. 2014;6(9):2309-2331. doi:10.3390/polym6092309
  142. Afzal O, Altamimi ASA, Nadeem MS, Alzarea SI, Almalki WH, Tariq A, et al. Nanoparticles in Drug Delivery: From History to Therapeutic Applications. Nanomaterials. 2022;12(24):4494. doi:10.3390/nano12244494
  143. Bassous N, Cooke JP, Webster TJ. Enhancing Stent Effectiveness with Nanofeatures. Methodist DeBakey Cardiovascular Journal. 2016;12(3):163. doi:10.14797/mdcj-12-3-163
  144. Tewabe A, Abate A, Tamrie M, Seyfu A, Abdela Siraj E. Targeted Drug Delivery — From Magic Bullet to Nanomedicine: Principles, Challenges, and Future Perspectives. Journal of Multidisciplinary Healthcare. 2021;Volume14:1711-1724. doi:10.2147/jmdh.s313968
  145. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nature Reviews Drug Discovery. 2020;20(2):101-124. doi:10.1038/s41573-020-0090-8
  146. Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharmaceutical Journal. 2018;26(1):64-70. doi:10.1016/j.jsps.2017.10.012
  147. Alghamdi MA, Fallica AN, Virzì N, Kesharwani P, Pittalà V, Greish K. The Promise of Nanotechnology in Personalized Medicine. Journal of Personalized Medicine. 2022;12(5):673. doi:10.3390/jpm12050673
  148. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Frontiers in Molecular Biosciences. 2020;7. doi:10.3389/fmolb.2020.00193
  149. Fernandez-Fernandez A, Manchanda R, McGoron AJ. Theranostic Applications of Nanomaterials in Cancer: Drug Delivery, Image-Guided Therapy, and Multifunctional Platforms. Applied Biochemistry and Biotechnology. 2011;165(7-8):1628-1651. doi:10.1007/s12010-011-9383-z
  150. Tewabe A, Abate A, Tamrie M, Seyfu A, Abdela Siraj E. Targeted Drug Delivery — From Magic Bullet to Nanomedicine: Principles, Challenges, and Future Perspectives. Journal of Multidisciplinary Healthcare. 2021;Volume14:1711-1724. doi:10.2147/jmdh.s313968
  151. Sim S, Wong N. Nanotechnology and its use in imaging and drug delivery (Review). Biomedical Reports. 2021;14(5). doi:10.3892/br.2021.1418
  152. Omidian H, Babanejad N, Cubeddu LX. Nanosystems in Cardiovascular Medicine: Advancements, Applications, and Future Perspectives. Pharmaceutics. 2023;15(7):1935. doi:10.3390/pharmaceutics15071935
  153. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. Journal of Nanobiotechnology. 2018;16(1). doi:10.1186/s12951-018-0392-8
  154. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. Journal of Nanobiotechnology. 2018;16(1). doi:10.1186/s12951-018-0392-8
  155. . Moahamed Sikkander A, Manisankar P, Vedhi C Utilization of sodium montmorillonite clay for enhanced electrochemical sensing of amlodipine,Indian Journal of Chemistry-Section A[IJCA] 55 [5], 571-575DOI: 10.56042/ijca.v55i5.11669
  156. Sivakumar R, Gopalakrishnan P, Abdul Razak MS. Comparative analysis of anti-reflection coatings on solar PV cells through TiO2and SiO2nanoparticles. Pigment & Resin Technology. 2021;51(2):171-177. doi:10.1108/prt-08-2020-0084
  157. Mohamed Sikkander A, Nasri NS., Review on Inorganic Nano crystals unique benchmark of Nanotechnology, Moroccan Journal of Chemistry 1 [2], 1-2 [2013] 47-54. https://doi.org/10.48317/IMIST.PRSM/morjchem-v1i2.1892
  158. Mohamed Sikkander A., Bassyouni F, Yasmeen K, Mishra S.R, Lakshmi V.V. Synthesis of Zinc Oxide and Lead Nitrate Nanoparticles and their Applications: Comparative Studies of Bacterial and Fungal [E. coli, A. Niger]. J. Appl. Organomet. Chem., 2023, 3[4], 255-267. https://doi.org/10.48309/JAOC.2023.415886.1115
Support